Los Angeles Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23M | Sell |
407,379
-704,319
| -63% | -$41.1M | 0.09% | 175 |
|
|
2025
Q4 | $57.7M | Sell |
1,111,698
-220,700
| -17% | -$12M | 0.2% | 92 |
|
|
2025
Q3 | $72.2M | Buy |
1,332,398
+1,054,209
| +379% | +$60.3M | 0.24% | 80 |
|
|
2025
Q2 | $15.3M | Buy |
278,189
+137,135
| +97% | +$8.08M | 0.06% | 200 |
|
|
2025
Q1 | $9.97M | Buy |
141,054
+102,525
| +266% | +$6.9M | 0.04% | 223 |
|
|
2024
Q4 | $2.53M | Buy |
38,529
+28,431
| +282% | +$1.9M | 0.01% | 397 |
|
|
2024
Q3 | $710K | Buy |
+10,098
| New | +$844K | ﹤0.01% | 760 |
|
|
2024
Q1 | – | Sell |
-6,911
| Closed | -$666K | – | 1134 |
|
|
2023
Q4 | $666K | Buy |
+6,911
| New | +$611K | ﹤0.01% | 797 |
|
|
2023
Q3 | – | Sell |
-62,126
| Closed | -$5.39M | – | 1129 |
|
|
2023
Q2 | $5.39M | Sell |
62,126
-13,583
| -18% | -$1.28M | 0.02% | 327 |
|
|
2023
Q1 | $7.36M | Sell |
75,709
-1,212
| -2% | -$126K | 0.03% | 305 |
|
|
2022
Q4 | $7.96M | Buy |
+76,921
| New | +$7.22M | 0.04% | 316 |
|
|
2020
Q3 | – | Sell |
-13,570
| Closed | -$1.67M | – | 1435 |
|
|
2020
Q2 | $1.67M | Buy |
13,570
+2,602
| +24% | +$259K | 0.01% | 666 |
|
|
2020
Q1 | $927K | Sell |
10,968
-3,980
| -27% | -$343K | 0.01% | 731 |
|
|
2019
Q4 | $1.26M | Buy |
+14,948
| New | +$1.13M | 0.01% | 767 |
|
|
2019
Q2 | – | Sell |
-12,688
| Closed | -$1.13M | – | 1348 |
|
|
2019
Q1 | $1.13M | Sell |
12,688
-770
| -6% | -$71.4K | 0.01% | 816 |
|
|
2018
Q4 | $1.15M | Sell |
13,458
-17,360
| -56% | -$1.65M | 0.01% | 691 |
|
|
2018
Q3 | $2.99M | Buy |
30,818
+13,470
| +78% | +$1.34M | 0.02% | 566 |
|
|
2018
Q2 | $1.63M | Buy |
17,348
+12,120
| +232% | +$1.06M | 0.01% | 752 |
|
|
2018
Q1 | $424K | Sell |
5,228
-2,170
| -29% | -$186K | ﹤0.01% | 1081 |
|
|
2017
Q4 | $660K | Sell |
7,398
-66,153
| -90% | -$5.75M | ﹤0.01% | 972 |
|
|
2017
Q3 | $6.84M | Buy |
73,551
+40,357
| +122% | +$3.57M | 0.04% | 378 |
|
|
2017
Q2 | $3.02M | Buy |
+33,194
| New | +$3.02M | 0.02% | 526 |
|
|
2017
Q1 | – | Sell |
-34,542
| Closed | -$2.86M | – | 1151 |
|
|
2016
Q4 | $2.86M | Sell |
34,542
-78,978
| -70% | -$6.79M | 0.02% | 492 |
|
|
2016
Q3 | $10.5M | Buy |
113,520
+110,385
| +3,521% | +$10.4M | 0.09% | 287 |
|
|
2016
Q2 | $244K | Buy |
+3,135
| New | +$267K | ﹤0.01% | 1109 |
|
|
2015
Q4 | – | Sell |
-20,195
| Closed | -$2.13M | – | 1125 |
|
|
2015
Q3 | $2.13M | Buy |
20,195
+1,460
| +8% | +$195K | 0.02% | 536 |
|
|
2015
Q2 | $2.56M | Sell |
18,735
-77,958
| -81% | -$9.66M | 0.02% | 518 |
|
|
2015
Q1 | $12.1M | Buy |
+96,693
| New | +$10.2M | 0.11% | 232 |
|
|
2014
Q2 | – | Sell |
-26,365
| Closed | -$1.8M | – | 1207 |
|
|
2014
Q1 | $1.8M | Sell |
26,365
-23,450
| -47% | -$1.73M | 0.02% | 510 |
|
|
2013
Q4 | $3.5M | Sell |
49,815
-90,555
| -65% | -$6.15M | 0.04% | 394 |
|
|
2013
Q3 | $10.1M | Buy |
140,370
+21,135
| +18% | +$1.4M | 0.13% | 224 |
|
|
2013
Q2 | $6.65M | Buy |
+119,235
| New | +$7.43M | 0.09% | 242 |
|
Other funds holding BMRN
VCM
VPM
Los Angeles Capital Management's BMRN Position: Q1 2026 in Review
Los Angeles Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 63% in Q1 2026, selling an estimated $41.1M and leaving 407,379 shares worth $23M. The position accounts for 0.09% of the portfolio, ranked #175.
Los Angeles Capital Management first reported a position in BMRN in Q2 2013 and has held it in 32 quarters since. The position peaked at $72.2M in Q3 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Los Angeles Capital Management held 407,379 shares of BioMarin Pharmaceuticals worth $23M as of Q1 2026.
- Los Angeles Capital Management sold 704,319 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $41.1M.
- BioMarin Pharmaceuticals made up 0.09% of Los Angeles Capital Management's portfolio in Q1 2026, its #175 holding.
- Los Angeles Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
- Los Angeles Capital Management's BioMarin Pharmaceuticals position peaked at $72.2M in Q3 2025.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.